ACAD (ACADIA Corp) יחס שווי שוק לשווי בספרים

ACADIA Pharmaceuticals (ACAD) is developing therapies for rare brain pathologies, leveraging the success of Nuplazid and Daybue alongside merger prospects. Financial stability is increasing due to regular payments from drug sales, with the indicator standing at 2.61. Production efficiency is ensured through logistics automation and external outsourcing. This chart of share price quotes confirms the current market dynamics of this biopharmaceutical business.

Diversifying its portfolio of CNS disorder treatments allows ACADIA Pharmaceuticals (ACAD) to capitalize on its intellectual property through a market premium over net assets. This indicator measures the gap between market value and book value, reflecting investor expectations regarding future revenues from new drugs. By analyzing the price-to-book ratio trend, one can determine the degree of stock overvaluation and the existence of a safety margin during market shocks.